Embark Healthcare

Embark Healthcare is a private U.S. pharmaceutical company focused on drug repurposing, which it describes as an "Indications Discovery Company" model. Formerly known as Carrot Capital Healthcare Partners, the company identifies new indications for existing drugs, adds intellectual property and regulatory exclusivity strategies, and advances assets into later-stage development through a family of portfolio companies. Its disclosed programs include CIRARA for large core ischemic stroke and CNS edema, BRAVYL for neurodegenerative diseases including ALS, CIQUAAX and LIVANTRA for liver disease-related conditions, and LORAZOL for metastatic melanoma. Embark operates through affiliated entities including Remedy Pharmaceuticals, Woolsey Pharmaceuticals, Martin Pharmaceuticals, and Learmont Pharmaceuticals, and has highlighted acquisition and licensing availability for several assets. Overall, the company is positioned as a specialty repurposing-focused therapeutic developer rather than a de novo drug discovery company.